Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
Date:5/9/2011

n January 2011, we received a $15 million milestone payment from Bayer Healthcare AG (Bayer) triggered by the initiation of a Phase 2 clinical study of BAY-86-9766 (RDEA119) in combination with sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals) in patients with hepatocellular carcinoma, or primary liver cancer.  BAY 86-9766 (RDEA119) is a potent, non-ATP competitive, highly selective inhibitor of mitogen-activated ERK kinase (MEK).
  • In April 2011, we announced that the following abstracts would be presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) on May 26, 2011 in London, UK:
  • Additional results from our Phase 2b study evaluating lesinurad in combination with allopurinol in gout patients not adequately responding to allopurinol;
  • Additional results from a completed Phase 1b study evaluating the combination of lesinurad and febuxostat in gout patients; and
  • Data from a completed preclinical study of lesinurad's effect on the hyperuricemia caused by the commonly used diuretic, hydrochlorothiazide.
  • In the third quarter, we expect to meet with the U.S. Food and Drug Administration to finalize the design of our Phase 3 program for lesinurad.

  • First Quarter 2011 Financial ResultsAs of March 31, 2011, we had $156.8 million in cash, cash equivalents and short-term investments and $2.0 million in receivables, compared to $80.6 million in cash, cash equivalents and short-term investments and $17.0 million in receivables as of December 31, 2010.

    The net increase in cash, cash equivalents and short-term investments in 2011 was due primarily to our public offering of common stock, which was completed in February 2011 and resulted in net proceeds to us of $78.1 million, and the receipt in January 2011 of a $15.0 million milestone payment under our global license agreement with Bayer HealthCare AG (Bayer).  These increases were partia
    '/>"/>

    SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
    2. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
    3. Ardea Biosciences Prices Public Offering of Common Stock
    4. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    8. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
    10. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
    11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
    (Date:12/15/2014)... , Dec. 15, 2014 Organovo ... biology company focused on delivering breakthrough 3D bioprinting ... industry and collaborators of its exVive3D TM ... widely available in full commercial release on November ... field, resulting in several awards for innovation. ...
    (Date:12/13/2014)... MaRS and Virgin Unite Canada, the non-profit foundation of the ... support Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... MaRS Centre to announce the new partnership, which includes the ... has $1 million in seed capital provided by Virgin Unite ... Innovation Foundation, founded by Alison Lawton . ...
    (Date:12/13/2014)... According to population studies: “North Carolina ... and 2030." If a population explosion like that actually ... state in the country. , To that end, North ... of North Carolina Forum on December 16th to ask ... necessary infrastructure in place? Enough clean water? And will ...
    Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2
    ... as Lead Epidemiologist, RALEIGH, N.C., Oct. 27 ... today the appointment of Dr.,Jerome Wilson as Senior ... Epidemiologist, Dr. Wilson is responsible for providing consulting,services ... PRA provides extensive Phase IV Post-Marketing services to,pharmaceutical ...
    ... October 27 Stallergenes has,just obtained authorization (IND(1)) from ... in the United States with Oralair(R) Grasses in,the treatment ... The aim of the study, which will be conducted ... to confirm the efficacy and good,tolerance of the product ...
    ... Beckman,Coulter, Inc. (NYSE: BEC ), a ... simplify, automate, and innovate complex biomedical,testing, announced ... and chief executive officer, will present at ... 4, 2008 at 1:20 p.m.,(ET)., (Logo: ...
    Cached Biology Technology:Jerome Wilson Joins PRA International's Late Phase Service Group 2Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009 2Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009 3
    (Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
    (Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
    (Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
    Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
    ... Robert Linhardt has spent years stitching together minuscule carbohydrates ... commonly used and controversial blood thinner heparin. At the national ... Linhardt announced that his research team may have accomplished this ... is the largest dose of heparin ever created in the ...
    ... date for bipolar disorder has implicated machinery involved in the ... in part by the National Institute of Mental Health, part ... the disorder and variation in two genes that make components ... and out of cells, including neurons. "A neuron,s ...
    ... CHAMPAIGN, Ill. Understanding the form and function ... becoming faster and easier, thanks to the work ... combining custom-built spectrometers, novel probe designs and faster ... professor Chad Rienstra has developed unique capabilities for ...
    Cached Biology News:Researchers create safer alternative to heparin 2Largest study of its kind implicates gene abnormalities in bipolar disorder 2Improved technique determines structure in membrane proteins 2
    ... mobility shift assay (EMSA) is a powerful ... to as gel shift or gel retardation, ... that when subjected to electrophoresis, free DNA ... The Pierce LightShift Chemiluminescent EMSA Kit is ...
    ... The Cell Lab Quantas unique ... provides unsurpassed population resolution capabilities and ... has multiple excitation wavelengths, including UV, ... variety of multi-color applications typically only ...
    ... Kit delivers a novel procedure for the ... of whole genome DNA from small samples. ... a quick and highly reproducible amplification and ... of a REPLI-g Mini Kit module (QIAGEN) ...
    ... be superior to transfection in some applications. ... PULSin you can study lethal proteins and ... proteins in cells. Likewise, delivery of blocking ... RNA interference experiments. ,With PULSin you ...
    Biology Products: